Natriuretic peptides: Markers or modulators of cardiac hypertrophy?

Trends in Endocrinology and Metabolism

Volumn 14, Issue 9, 2003, Pages 411-416

  Gardner, David G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; OMAPATRILAT; VASOPEPTIDASE INHIBITOR;

ANTIMITOTIC ACTIVITY; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIURESIS; DRUG EFFECT; DRUG INDICATION; DYSPNEA; GENE EXPRESSION REGULATION; GERIATRIC PATIENT; HEART FAILURE; HEART HYPERTROPHY; HOMEOSTASIS; HUMAN; MITOSIS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VASODILATATION;

EID: 0242527373     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(03)00113-9     Document Type: Review

References (56)

1. Levin, E.R. et al. (1998) Natriuretic peptides. N. Engl. J. Med. 339, 321-328
2. Chien, K.R. et al. (1993) Transcriptional regulation during cardiac growth and development. Annu. Rev. Physiol. 55, 77-95
3. Mukoyama, M. et al. (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. J. Clin. Invest. 87, 1402-1412
4. Wei, C.M. et al. (1993) Natriuretic peptide system in human heart failure. Circulation 88, 1004-1009
5. Maack, T. et al. (1987) Physiological role of silent receptors of atrial natriuretic factor. Science 238, 675-678
6. Grepin, C. et al. (1994) A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol. Cell. Biol. 14, 3115-3129
7. Molkentin, J.D. et al. (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215-228
8. Charron, F. et al. (1999) Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol. Cell. Biol. 19, 4355-4365
9. Thuerauf, D.J. and Glembotski, C.C. (1997) Differential effects of protein kinase C, Ras and Raf-1 kinase on the induction of the cardiac B-type natriuretic peptide gene through a critical promoter-proximal M-CAT element. J. Biol. Chem. 272, 7464-7472
10. Dai, Y.S. et al. (2002) The transcription factors GATA4 and dHAND physically interact to synergistically activate cardiac gene expression through a p300-dependent mechanism. J. Biol. Chem. 277, 24390-24398
11. Ogawa, E. et al. (2002) Fibronectin signaling stimulates BNP gene transcription by inhibiting neuron-restrictive silencer element-dependent repression. Cardiovasc. Res. 53, 451-459
12. Bhalla, S.S. et al. (2001) Cooperative activation by GATA-4 and YY1 of the cardiac B-type natriuretic peptide promoter. J. Biol. Chem. 276, 11439-11445
13. Charron, F. et al. (2001) Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev. 15, 2702-2719
14. Hautala, N. et al. (2001) Pressure overload increases GATA4 binding activity via endothelin 1. Circulation 103, 730-735
15. Marttila, M. et al. (2001) GATA4 mediates activation of the B-type natriuretic peptide gene expression in response to hemodynamic stress. Endocrinology 142, 4693-4700
16. Liang, F. and Gardner, D.G. (1999) Mechanical strain activates BNP gene transcription through p38/NF-κB-dependent mechanism. J. Clin. Invest. 104, 1603-1612
17. Liang, F. et al. (2003) Triiodothyronine increases BNP gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. J. Biol. Chem. 278, 15073-15083
18. Wu, J. et al. (1996) 1,25 (OH)2 vitamin D and retinoic acid prevent hypertrophy of neonatal cardiac myocytes. J. Clin. Invest. 97, 1577-1588
19. Tsutamoto, T. et al. (1997) Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation 96, 509-516
20. Koglin, J. et al. (2001) Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J. Am. Coll. Cardiol. 38, 1934-1941
21. Bettencourt, P. et al. (2002) Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am. J. Med. 113, 215-219
22. Yoshimura, M. et al. (2002) B-type natriuretic peptide as a marker of effects of enalapril in patients with heart failure. Am. J. Med. 112, 716-720
23. Lee, S.C. et al. (2002) The potential of brain natriuretic peptide as a biomarker for New York heart association class during the outpatient treatment of heart failure. J. Card. Fail. 8, 149-154
24. Troughton, R.W. et al. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130
25. Davis, M. et al. (1994) Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343, 440-444
26. Morrison, L.K. et al. (2002) Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J. Am. Coll. Cardiol. 39, 202-209
27. Maisel, A.S. et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347, 161-167
28. Richards, A.M. et al. (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97, 1921-1929
29. McDonagh, T.A. et al. (1998) Biochemical detection of left ventricular systolic dysfunction. Lancet 351, 9-13
30. Yamamoto, K. et al. (1996) Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28, 988-994
31. Vasan, R.S. et al. (2002) Plasma natriuretic peptides for community screening for left ventricular-hypertrophy and systolic dysfunction. JAMA 288, 1252-1259
32. Davis, K.M. et al. (1992) Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. JAMA 267, 2625-2629
33. Wallen, T. et al. (1997) Brain natriuretic peptide predicts mortality in the elderly. Heart 77, 264-267
34. Ueda, R. et al. (2003) Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am. J. Med. 114, 266-270
35. Redfield, M.M. et al. (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol. 40, 976-982
36. Sayama, H. et al. (1999) Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron. Artery Dis. 10, 537-540
37. Yoshimura, M. et al. (1991.) Hemodynamic, renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84, 1581-1588
38. Hobbs, R.E. et al. (1996) Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 78, 896-901
39. Marcus, L.S. et al. (1996) Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 94, 3184-3189
40. Mills, R.M. et al. (1999) Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure. J. Am. Coll. Cardiol. 34, 155-162
41. Colucci, W.S. et al. (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med. 343, 246-253
42. Chen, H.H. et al. (2001) Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension 38, 187-191
43. Rouleau, J.L. et al. (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 356, 615-620
44. Packer, M. et al. (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation 106, 920-926
45. Cao, L. and Gardner, D.G. (1995) Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 25, 227-234
46. Horio, T. et al. (2000) Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 35, 19-24
47. Calderone, A. et al. (1998) Nitric oxide, atrial natriuretic peptide and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest. 101, 812-818
48. Silberbach, M. et al. (1999) Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. J. Biol. Chem. 274, 24858-24864
49. Cameron, V. et al. (2000) Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. Endocrinology 141, 4690-4697
50. Tsuruda, T. et al. (2002) Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ. Res. 91, 1127-1134
51. Tamura, N. et al. (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. U. S. A. 97, 4239-4244
52. Oliver, P.M. et al. (1997) Hypertension, cardiac hypertrophy and sudden death in mice lacking natriuretic peptide receptor A. Proc. Natl. Acad. Sci. U. S. A. 94, 14730-14735
53. Lopez, M.J. et al. (1995) Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378, 65-68
54. Knowles, J.W. et al. (2001) Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J. Clin. Invest. 107, 975-984
55. Kishimoto, I. et al. (2001) A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 98, 2703-2706
56. Holtwick, R. et al. (2003) Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase. J. Clin. Invest. 111, 1399-1407